# **The Medical Letter**<sup>®</sup>

on Drugs and Therapeutics

#### Volume 64

May 16, 2022

ISSUE No.

IN THIS ISSUE

In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis .........p 78

### Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769 The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769

### The Medical Letter<sup>®</sup> on Drugs and Therapeutics

Volume 64 (Issue 1650)

May 16, 2022

**Take CME Exams** 

#### **IN BRIEF**

## OTC Alcaftadine (*Lastacaft Once Daily Relief*) for Allergic Conjunctivitis

The ophthalmic  $H_1$ -antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as *Lastacaft Once Daily Relief* (Allergan) for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children  $\geq$ 2 years old. It is the third ophthalmic antihistamine to be approved for over-thecounter (OTC) use (see Table 1).

Ophthalmic  $H_1$ -antihistamines are at least as effective as oral second-generation  $H_1$ antihistamines for prevention of ocular itching due to allergic conjunctivitis, and they take effect within a few minutes.<sup>1</sup> They are generally not effective in relieving erythema. Alcaftadine, azelastine, bepotastine, epinastine, ketotifen, and olopatadine also have mast cell-stabilizing effects. Ophthalmic vasoconstrictors such as naphazoline reduce erythema, but they should generally be avoided because they can cause rebound hyperemia.

**EFFICACY** – Once-daily use of alcaftadine has been shown to prevent ocular itching due to allergic conjunctivitis for up to 16 hours.<sup>2</sup> In a pooled analysis of two double-masked conjunctival allergen challenge (CAC) trials in patients with a history of ocular allergies, alcaftadine 0.25% was significantly more effective than olopatadine 0.2% in preventing CAC-induced ocular itching 16 hours after instillation.<sup>3</sup>

**ADVERSE EFFECTS** – Alcaftadine ophthalmic solution is generally well tolerated. Like most ophthalmic antihistamine products, it contains the preservative benzalkonium chloride, which can cause burning and stinging. Refrigerating the drug before use may mitigate this effect.

Drug	Formulations (Sizes)	Usual Dosage <sup>1</sup>	Age	Rx/OTC	Cost <sup>2,3</sup>
Alcaftadine – Lastacaft Once Daily Relief (Allergan)	0.25% soln* (5 mL)	1 drop once/day	$\geq 2 \text{ yrs}$	OTC	\$19.00
Azelastine – generic	0.05% soln* (6 mL)	1 drop bid	≥3 yrs	Rx	35.00
Bepotastine – <i>Bepreve</i> (Bausch + Lomb)	1.5% soln* (5, 10 mL)	1 drop bid	≥2 yrs	Rx	256.10
Cetirizine – Z <i>erviate</i> (Eyevance)	0.24% soln* (0.2 mL)4	1 drop bid (8 hours apart)	≥2 yrs	Rx	229.10
Epinastine – generic	0.05% soln* (5 mL)	1 drop bid	≥2 yrs	Rx	85.60
Ketotifen⁵ – generic Alaway (Bausch + Lomb) Zaditor (Alcon)	0.025% soln* (5, 10 mL) 0.025% soln* (5 mL)	1 drop bid (q8-12h)	≥3 yrs	OTC OTC OTC	11.00 11.00 12.00
Alaway Preservative Free	0.025% soln (0.4 mL) <sup>6</sup>	1 drop bid	≥3 yrs	OTC	15.00
Olopatadine – generic	0.1% soln* (5 mL) 0.2% soln* (2.5 mL)	1 drop bid (q6-8h) 1 drop once/day	≥2 yrs ≥2 yrs	Rx Rx	7.60 14.00
Pataday Twice Daily Relief (Alcon)	0.1% soln* (5 mL)	1 drop bid (q6-8h)	≥2 yrs	OTC	13.00
Pataday Once Daily Relief Pataday Once Daily Relief Extra Strength	0.2% soln* (2.5 mL) 0.7% soln* (2.5 mL)	1 drop once/day 1 drop once/day	≥2 yrs ≥2 yrs	OTC OTC	19.00 20.00

OTC = available over the counter; Rx = available by prescription only; soln = solution

\*Contains benzalkonium chloride (preservative).

1. Refrigerating the product before use could reduce stinging and burning.

2. Approximate WAC for one bottle or carton of the smallest available size (prescription products). WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. April 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/policies/drug-pricing-policy.

Approximate cost for one bottle or carton of the smallest available size at walmart.com (OTC products). Accessed April 28, 2022.

4. Available in cartons of 30 single-use 0.2-mL containers.

5. A contact lens that releases ketotifen (Acuvue Theravision) is also FDA-approved and will be marketed in late 2022 (Med Lett Drugs Ther 2022; 64:60).

6. Available in cartons of 20 single-dose 0.4-mL vials

#### The Medical Letter®

Vol. 64 (1650)

DOSAGE AND ADMINISTRATION - Lastacaft Once Daily Relief is available in a 5-mL bottle and in a twin pack containing two 5-mL bottles. The recommended dosage is one drop in each affected eye once daily. Other ophthalmic products should not be used for at least 5 minutes after instillation of alcaftadine. Contact lenses should be removed before use of the drug; they can be reinserted after 10 minutes.

- 1. Drugs for allergic rhinitis and allergic conjunctivitis. Med Lett Drugs Ther 2021; 63:57.
- 2. Alcaftadine (Lastacaft) for allergic conjunctivitis. Med Lett Drugs Ther 2011: 53:19.
- 3. EB McLaurin et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther 2014; 31:1059.

PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School VICE PRESIDENT AND EDITOR IN CHIEF. Jean-Marie Pflomm, Pharm.D.; ASSOCIATE EDITORS: Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. CONSULTING EDITORS: Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; EDITORIAL ASSISTANT: Karrie F

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; EXECUTIVE DIRECTOR OF SALES: Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; INTERIM PUBLISHER: Jean-Marie Pflomm, Pharm.D.

Permissions:

#### Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission. Subscription Services

#### Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537 E-mail: custserv@medicalletter.org www.medicalletter.org

Get Connected: 💓 in 👖 🧭

**Customer Service:** 

Call: 800-211-2769 or 914-235-0500 To reproduce any portion of this issue, Fax: 914-632-1733 please e-mail your request to: please e-mail your request to: permissions@medicalletter.org

Copyright 2022. ISSN 0025-2859

Subscriptions (US): 1 year - \$159; 2 years - \$298; 3 years - \$398. \$65 per year for students, interns, residents, and fellows in the US and Canada. Reprints - \$45 per issue or article Site License Inquiries: E-mail: SubQuote@medicalletter.org Call: 800-211-2769

Special rates available for bulk subscriptions.

79